New smart drug targets Hard-to-Treat cancers

NCT ID NCT06303505

Recruiting now Disease control Sponsor: Tubulis GmbH Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called TUB-040 for people with ovarian cancer that no longer responds to platinum chemotherapy, or with a type of lung cancer that has come back. TUB-040 is an antibody-drug conjugate, meaning it delivers a powerful chemotherapy directly to cancer cells that have a specific marker (NaPi2b). The trial has two parts: first, finding the safest dose, and then comparing doses to see which works best. Participants receive the drug intravenously every three weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TUB-040 (an antibody-drug conjugate that delivers a chemotherapy drug directly to cancer cells)
What this could lead to: If successful, this could provide a new treatment option for patients with hard-to-treat ovarian or lung cancer who have run out of standard therapies.
What could go wrong: This is an early-phase trial (Phase 1/2a) with a small number of patients, so the drug may not work or may cause significant side effects. The cancer types are aggressive and resistant to current treatments, making success uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung adenocarcinoma non-small cell lung carcinoma ovarian cancer ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER OVARIAN CANCER

Contacts and locations

Locations

Arensia Exploratory Medicine
RECRUITING

Cluj-Napoca, Romania
Arensia Exploratory Medicine
RECRUITING

Kyiv, Ukraine
Charité Universitätsmedizin Berlin
RECRUITING

Berlin, 10117, Germany
Christ Hospital
RECRUITING

Cincinnati, Ohio, 45219, United States
Clínica universidad de Navarra
RECRUITING

Madrid, 28027, Spain
Guy's Hospital
RECRUITING

London, SE1 9RT, United Kingdom
Mount Sinai
RECRUITING

New York, New York, 10011, United States
NEXT Oncology Madrid
RECRUITING

Madrid, 28223, Spain
Next Oncology Dallas
RECRUITING

Irving, Texas, 75039, United States
Next Oncology Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
OU Health Stephenson Cancer Center
RECRUITING

Oklahoma City, Oklahoma, 73104, United States
Ohio State University
RECRUITING

Columbus, Ohio, 43210#, United States
The University of Alabama
RECRUITING

Birmingham, Alabama, 35294, United States
UZ Leuven
RECRUITING

Leuven, Belgium, 3000, Belgium
University Hospital Cologne Department of Internal Medicine I
RECRUITING

Cologne, 50937, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.